26 ott - Milano
IEO European Institute of Oncology
Postdoctoral Position Endocytosis, Signalling and Cancer Lab IEO
- European Institute of Oncology Milan, Italy € 36.000 per year gross About the Project: Breast cancer management is hindered by extensive molecular and phenotypic heterogeneity. Despite advances in molecular stratification and precision medicine, major unmet clinical needs persist, particularly in intermediate-risk Luminal breast cancer and triple-negative breast cancer (TNBC), the most aggressive subtype. Our laboratory has recently developed two multigene signatures: PetSign, capturing metabolic (glycolytic) alterations, and StemPrintER, reflecting the acquisition of cancer stem cell properties. This project aims to leverage these signatures to improve prognostic stratification of Luminal and TNBC patients and to identify FDA-approved drugs capable of targeting these phenotypes. Role and
Responsibilities:
Derivation of a PetSign risk score (PRS) and a StemPrintER risk score (SPRS); Benchmarking of PRS and SPRS vs. available BC predictors; Molecular and phenotypic validation in BC lines of genes of PetSign and StemPrintER.
Qualifications:
A PhD in Cancer Biology, Cell Biology, Molecular Biology, Systems Medicine or a related life sciences discipline; Strong experience in mammalian cell culture and functional assays; Experience in RNAseq, scRNAseq, and bioinformatics; Familiarity with phenotypic heterogeneity and functional characterization of cancer cell states; A genuine interest in translational cancer research. Deadline 21 November IEO
- European Institute of Oncology